Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1C3 | P42330 | 1/20 | 0.58 |
| ▸ | PPARG | P37231 | 1/20 | 0.57 |
| ▸ | STS | P08842 | 5/20 | 0.53 |
| ▸ | NR4A2 | P43354 | 4/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | KMO | O15229 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA9 | Q16790 | 1/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14562524 | 0.84 | PPARG (0.56) | AKR1C3PPARGSTSNR4A2KMT2A | |
| SCHEMBL32665541 | 0.84 | STS (0.51) | STSKMT2ACA12CA1CA2 | |
| SCHEMBL2964425 | 0.82 | PPARG (0.61) | AKR1C3PPARGSTSNR4A2KMT2A | |
| SCHEMBL20720014 | 0.81 | LCK (0.42) | AKR1C3PPARGKMT2ACA12CA1 | |
| SCHEMBL31448076 | 0.81 | KDM4E (0.59) | PPARGKMT2ACA1CA2CA9 | |
| SCHEMBL18507891 | 0.80 | CA1 (0.60) | PPARGSTSKMT2ACA1CA2 | |
| SCHEMBL32665549 | 0.80 | GSK3B (0.50) | PPARGSTS | |
| SCHEMBL32665022 | 0.80 | STS (0.47) | PPARGSTSKMT2A | |
| SCHEMBL17129794 | 0.80 | NPC1 (0.65) | KMT2A | |
| SCHEMBL4253998 | 0.78 | RAB9A (0.60) | AKR1C3PPARGSTSNR4A2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | TOPAZ THERAPEUTICS INC (US) | 2026-01-22 | — | — | US | disclosed |
| CN-119708120-A | Compound for targeting prostate specific membrane antigen and preparation method and application thereof | 复旦大学附属肿瘤医院 | 2025-03-28 | — | — | CN | disclosed |
| CN-119630970-A | Novel Kong Shanti and holes | 牛津纳米孔科技公开有限公司 | 2025-03-14 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260021192-A1 | PROTEINS HAVING A COVALENT WARHEAD | RIOX2, ORC3, DCLRE1A | AKR1C3 2060/4885PPARG 4667/4885STS 3493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.